510-62-3 Usage
Uses
Used in Pharmaceutical Industry:
3β,14-Dihydroxy-19-oxobufa-4,20,22-trienolide is used as a pharmaceutical agent for its anti-tumor, anti-inflammatory, and cardioactive effects. Its potent biological activities make it a promising candidate for the development of new drugs to treat various diseases.
Used in Cancer Treatment:
3β,14-Dihydroxy-19-oxobufa-4,20,22-trienolide is used as an anti-tumor agent, showing potential in the treatment of various types of cancer. Its potent biological activities make it a promising candidate for further research and development as a cancer therapeutic.
Used in Inflammation Management:
3β,14-Dihydroxy-19-oxobufa-4,20,22-trienolide is used as an anti-inflammatory agent, making it a potential candidate for the development of new treatments for inflammatory conditions.
Used in Cardiovascular Applications:
3β,14-Dihydroxy-19-oxobufa-4,20,22-trienolide is used for its cardioactive effects, making it a potential candidate for the development of new treatments for cardiovascular diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 510-62-3 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,1 and 0 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 510-62:
(5*5)+(4*1)+(3*0)+(2*6)+(1*2)=43
43 % 10 = 3
So 510-62-3 is a valid CAS Registry Number.
InChI:InChI=1/C24H30O5/c1-22-9-7-19-20(4-3-16-12-17(26)6-10-23(16,19)14-25)24(22,28)11-8-18(22)15-2-5-21(27)29-13-15/h2,5,12-14,17-20,26,28H,3-4,6-11H2,1H3/t17-,18+,19?,20?,22+,23+,24-/m0/s1
510-62-3Relevant academic research and scientific papers
Antiproliferative homoisoflavonoids and bufatrienolides from Urginea depressa
Dai, Yumin,Harinantenaina, Liva,Brodie, Peggy J.,Goetz, Michael,Shen, Yongchun,Tendyke, Karen,Kingston, David G. I.
, p. 865 - 872 (2013/06/27)
Investigation of the South African plant Urginea depressa Baker (Asparagaceae Juss.) for antiproliferative activity against the A2780 ovarian cancer cell line led to the isolation of the six new homoisoflavonoids urgineanins A-F (1-6), the two known bufatrienolides 7 and 9, and the new bufatrienolides urginins B and C (8 and 10). Structures were elucidated based on analysis of their 1D and 2D NMR spectra, electronic circular dichroism, and mass spectrometric data. Five of the six new homoisoflavonoids had good antiproliferative activity against the A2780 ovarian cancer, A2058 melanoma, and H522-T1 human non-small-cell lung cancer cells, and urgineanin A (1) had submicromolar activity against all three cell lines. The four bufatrienolides 7-10 had strong antiproliferative activity against the same cell line, with IC50 values of 24.1, 11.2, 111, and 40.6 nM, respectively.
